Cerebrolysin vs Selank
A side-by-side research comparison of Cerebrolysin and Selank across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cerebrolysin | Selank |
|---|---|---|
| Full name | Cerebrolysin (Brain-Derived Peptide Preparation) | Selank (TP-7) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | Research compound |
| Mechanism | Contains fragments mimicking NGF, BDNF, GDNF, CNTF. Enhances synaptic plasticity, promotes neuronal sprouting, reduces amyloid-beta, and stabilizes calcium homeostasis. | Modulates GABA-A allosteric sites, increases BDNF, stabilizes enkephalin degradation, and influences serotonin metabolism. Enhances IL-6 and Th1/Th2 balance. |
| Molecular weight | <10,000 Da (peptide fraction) | 751.9 Da |
| Half-life | 4-6 hours | 3-5 min (IV) / 15-30 min (intranasal) |
| Bioavailability | High (IM/IV) | Moderate (intranasal) |
| Typical dose | 5-30 mL | 250-750 mcg per spray dose |
| Frequency | Daily for 10-20 days | 2-3x daily |
| Route | Intramuscular or IV | Intranasal spray |
Cerebrolysin reported benefits
- Neurotrophic support
- Stroke recovery
- Memory improvement
- Neuroprotection
- Synaptic plasticity
- Approved in 40+ countries
Selank reported benefits
- Anxiolytic without sedation
- Improved memory/learning
- Cognitive flexibility
- Immune modulation
- BDNF upregulation
- No addiction
Related comparisons
Research and educational reference only. Not medical advice.